Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hema
Hema Budaraju, Sunnyvale, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110145335 | PRESENTING A GEMSTONE IN A SETTING - A ring design machine receives one or more selections of gemstones and one or more selections of settings and allows a user to “mix and match” gemstones and settings and view a selected gemstone in a compatible setting for that gemstone. To present the gemstone in the setting, the ring design machine presents a combination image that depicts the gemstone in the setting. The ring design machine, which may be implemented using a computer programmed by software, may present the combination image to the user in response to receiving a selection of the gemstone and a selection of the setting from the user via a network. | 06-16-2011 |
Hema Dattani, Oxfordshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20090110634 | RADIOLABELLED NANOPARTICLES - The present invention relates to radiolabelled nanoparticles having a radioisotope non-covalently bonded thereto. The radiolabelled nanoparticles are useful as radiopharmaceuticals. Kits and methods of preparation of the radiolabelled nanoparticles are also disclosed. | 04-30-2009 |
Hema Gursahani, Foster City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100210676 | Chemically Modified Small Molecules - Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material. | 08-19-2010 |
| 20110160186 | Methods of Treating CYP2D6 Alternative Metabolizers - The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene. | 06-30-2011 |
Hema Masarapu, Hyderabad IN
| Patent application number | Description | Published |
|---|---|---|
| 20090087861 | Chimeric Tymovirus-like Particles and Process Thereof - The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The present disclosure provides a highly efficient means for differentiating Foot and Mouth Disease Virus (FMDV) infected animals from vaccinated animals. The present disclosure further provides a process for the production of chimeric TVLPs and a diagnostic kit for the determination of specific antibodies of FMDV to differentiate FMDV infected from vaccinated animals. The present disclosure also provides the use of the chimeric TVLPs for diagnostic purposes. | 04-02-2009 |